+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Src inhibitors in lung cancer: current status and future directions



Src inhibitors in lung cancer: current status and future directions



Clinical Lung Cancer 11(4): 238-242



Src tyrosine kinases regulate multiple genetic and signaling pathways involved in the proliferation, survival, angiogenesis, invasion, and migration of various types of cancer cells They are frequently expressed and activated in many cancer types, including lung cancer. Several Src inhibitors, including dasatinib, saracatinib, bosutinib, and KX2-391, are currently being investigated in clinical trials. Preliminary results of the use of single-agent Src inhibitors in unselected patients with lung cancer show that these inhibitors have a favorable safety profile and anticancer activity. Their combination with cytotoxic chemotherapy, other targeted therapy, and radiation therapy is currently being explored. In this review, we summarize the rationale for and the current status of Src inhibitor development and discuss future directions based on emerging preclinical data.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055896396

Download citation: RISBibTeXText

PMID: 20630825

DOI: 10.3816/clc.2010.n.030


Related references

Immune checkpoint inhibitors in lung cancer: current status and future directions. Chinese Clinical Oncology 6(2): 17, 2017

Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. Briefings in Functional Genomics 18(2): 147-156, 2019

Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions. Breast Care 13(1): 27-31, 2018

Telomerase inhibitors in cancer therapy: current status and future directions. Current Opinion in Investigational Drugs 4(6): 675-685, 2003

HER family inhibitors in pancreatic cancer: current status and future directions. Expert Opinion on Therapeutic Targets 11(3): 337-347, 2007

Screening for Lung Cancer: Current Status and Future Directions. Chest Journal 125(5): 158s-162s, 2004

PET scanning in lung cancer: current status and future directions. Seminars in Surgical Oncology 21(3): 149-155, 2003

Lung cancer chemoprevention current status and future directions. Current Respiratory Care Reports 1(1): 9-20, 2012

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion on Investigational Drugs 23(5): 611-628, 2014

Molecular pathology of lung cancer: current status and future directions. Tuberculosis and Respiratory Diseases 77(2): 49-54, 2014

Current status and future directions of surgery for lung cancer in China. Chinese Medical Journal 120(8): 619-621, 2007

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treatment Reviews 35(8): 685-691, 2009

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions. Frontiers in Oncology 5: 209, 2015

Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(8): 1294-1300, 2000

Chemotherapy with Platinum Compounds: Current Status and Future Directions. Volume 3: Dosing, Head and Neck Cancer, Genitourinary Cancer, Pediatric Cancer, Tumor of Unknown Origin, Dose Intensity, Future Directions. Kona, Hawaii, February 24-28, 1993. Seminars in Oncology 21(5 Suppl 12): 1-118, 1994